These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 16338342)
1. Amyloid imaging: from benchtop to bedside. Wu C; Pike VW; Wang Y Curr Top Dev Biol; 2005; 70():171-213. PubMed ID: 16338342 [TBL] [Abstract][Full Text] [Related]
2. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Kung MP; Hou C; Zhuang ZP; Skovronsky D; Kung HF Brain Res; 2004 Oct; 1025(1-2):98-105. PubMed ID: 15464749 [TBL] [Abstract][Full Text] [Related]
3. Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease? Nichols L; Pike VW; Cai L; Innis RB Biol Psychiatry; 2006 May; 59(10):940-7. PubMed ID: 16487944 [TBL] [Abstract][Full Text] [Related]
4. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829 [TBL] [Abstract][Full Text] [Related]
5. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Fagan AM; Mintun MA; Mach RH; Lee SY; Dence CS; Shah AR; LaRossa GN; Spinner ML; Klunk WE; Mathis CA; DeKosky ST; Morris JC; Holtzman DM Ann Neurol; 2006 Mar; 59(3):512-9. PubMed ID: 16372280 [TBL] [Abstract][Full Text] [Related]
6. [Introduction to and general remarks on molecular imaging]. Fukuda H; Okamura N Brain Nerve; 2007 Mar; 59(3):203-7. PubMed ID: 17370645 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. Mathis CA; Wang Y; Holt DP; Huang GF; Debnath ML; Klunk WE J Med Chem; 2003 Jun; 46(13):2740-54. PubMed ID: 12801237 [TBL] [Abstract][Full Text] [Related]
8. Detecting amyloid-β plaques in Alzheimer's disease. Baltes C; Princz-Kranz F; Rudin M; Mueggler T Methods Mol Biol; 2011; 711():511-33. PubMed ID: 21279620 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. Zhen W; Han H; Anguiano M; Lemere CA; Cho CG; Lansbury PT J Med Chem; 1999 Jul; 42(15):2805-15. PubMed ID: 10425090 [TBL] [Abstract][Full Text] [Related]
10. 11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease. Serdons K; Verduyckt T; Vanderghinste D; Borghgraef P; Cleynhens J; Van Leuven F; Kung H; Bormans G; Verbruggen A Eur J Med Chem; 2009 Apr; 44(4):1415-26. PubMed ID: 18992967 [TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Jack CR; Marjanska M; Wengenack TM; Reyes DA; Curran GL; Lin J; Preboske GM; Poduslo JF; Garwood M Neuroscientist; 2007 Feb; 13(1):38-48. PubMed ID: 17229974 [TBL] [Abstract][Full Text] [Related]
12. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Opazo C; Luza S; Villemagne VL; Volitakis I; Rowe C; Barnham KJ; Strozyk D; Masters CL; Cherny RA; Bush AI Aging Cell; 2006 Feb; 5(1):69-79. PubMed ID: 16441845 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice. Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020 [TBL] [Abstract][Full Text] [Related]
14. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. Agdeppa ED; Kepe V; Petri A; Satyamurthy N; Liu J; Huang SC; Small GW; Cole GM; Barrio JR Neuroscience; 2003; 117(3):723-30. PubMed ID: 12617976 [TBL] [Abstract][Full Text] [Related]
15. [(18)F]-labeled isoindol-1-one and isoindol-1,3-dione derivatives as potential PET imaging agents for detection of beta-amyloid fibrils. Lee JH; Byeon SR; Kim Y; Lim SJ; Oh SJ; Moon DH; Yoo KH; Chung BY; Kim DJ Bioorg Med Chem Lett; 2008 Oct; 18(20):5701-4. PubMed ID: 18835777 [TBL] [Abstract][Full Text] [Related]
16. Abeta amyloid deposition in the language system and how the brain responds. Nelissen N; Vandenbulcke M; Fannes K; Verbruggen A; Peeters R; Dupont P; Van Laere K; Bormans G; Vandenberghe R Brain; 2007 Aug; 130(Pt 8):2055-69. PubMed ID: 17586869 [TBL] [Abstract][Full Text] [Related]
17. Visualizing pathology deposits in the living brain of patients with Alzheimer's disease. Kepe V; Huang SC; Small GW; Satyamurthy N; Barrio JR Methods Enzymol; 2006; 412():144-60. PubMed ID: 17046657 [TBL] [Abstract][Full Text] [Related]
18. [Neuroimaging Alzheimer's disease: early diagnosis, monitoring, and mechanism understanding]. Chételat G Med Sci (Paris); 2011 Feb; 27(2):193-8. PubMed ID: 21382329 [TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease. Kantarci K Expert Rev Neurother; 2005 Sep; 5(5):663-70. PubMed ID: 16162090 [TBL] [Abstract][Full Text] [Related]
20. 2-Arylimidazo[2,1-b]benzothiazoles: a new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain. Alagille D; DaCosta H; Baldwin RM; Tamagnan GD Bioorg Med Chem Lett; 2011 May; 21(10):2966-8. PubMed ID: 21458990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]